PT2144905E - Agentes terapêuticos - Google Patents

Agentes terapêuticos

Info

Publication number
PT2144905E
PT2144905E PT87425203T PT08742520T PT2144905E PT 2144905 E PT2144905 E PT 2144905E PT 87425203 T PT87425203 T PT 87425203T PT 08742520 T PT08742520 T PT 08742520T PT 2144905 E PT2144905 E PT 2144905E
Authority
PT
Portugal
Prior art keywords
therapeutic agents
therapeutic
agents
Prior art date
Application number
PT87425203T
Other languages
English (en)
Inventor
Mark T Bilodeau
Kausik K Nanda
B Wesley Trotter
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39540659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2144905(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PT2144905E publication Critical patent/PT2144905E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
PT87425203T 2007-04-04 2008-04-03 Agentes terapêuticos PT2144905E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92175907P 2007-04-04 2007-04-04

Publications (1)

Publication Number Publication Date
PT2144905E true PT2144905E (pt) 2013-02-26

Family

ID=39540659

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87425203T PT2144905E (pt) 2007-04-04 2008-04-03 Agentes terapêuticos

Country Status (33)

Country Link
US (3) US8252799B2 (pt)
EP (1) EP2144905B1 (pt)
JP (2) JP5097265B2 (pt)
KR (1) KR101562835B1 (pt)
CN (1) CN101675046B (pt)
AU (1) AU2008236705B2 (pt)
BR (1) BRPI0809492A2 (pt)
CA (1) CA2682494C (pt)
CO (1) CO6300938A2 (pt)
CR (1) CR11047A (pt)
CY (1) CY1113649T1 (pt)
DK (1) DK2144905T3 (pt)
DO (1) DOP2009000232A (pt)
EC (1) ECSP099674A (pt)
ES (1) ES2398312T3 (pt)
GT (1) GT200900258A (pt)
HK (1) HK1134291A1 (pt)
HR (1) HRP20130041T8 (pt)
IL (1) IL201235A (pt)
MA (1) MA31323B1 (pt)
MX (1) MX2009010678A (pt)
MY (1) MY153868A (pt)
NI (1) NI200900175A (pt)
NZ (1) NZ580167A (pt)
PL (1) PL2144905T3 (pt)
PT (1) PT2144905E (pt)
RS (1) RS52661B (pt)
RU (1) RU2468025C2 (pt)
SI (1) SI2144905T1 (pt)
SV (1) SV2009003380A (pt)
UA (1) UA96015C2 (pt)
WO (1) WO2008124030A1 (pt)
ZA (1) ZA200906525B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000032987A (ja) * 1998-07-16 2000-02-02 Dai Ichi Seiyaku Co Ltd Ｄｎａ
ES2326078T3 (es) 2002-08-22 2009-09-30 Dainippon Sumitomo Pharma Co., Ltd. Medicamento destinado al sindrome de la disfuncion de integracion.
CN1826338B (zh) 2003-06-23 2011-07-13 大日本住友制药株式会社 老年性痴呆症治疗药
US20070160537A1 (en) 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
UA96015C2 (en) 2007-04-04 2011-09-26 Mepk Шарп Энд Доме Корп. Therapeutic agents
US20110124659A1 (en) * 2009-11-17 2011-05-26 Dainippon Sumitomo Pharma Co., Ltd. Cycloalkane derivative
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
EP4327872A3 (en) 2011-03-18 2024-07-10 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN103207246B (zh) * 2012-12-21 2017-10-10 北京万全德众医药生物技术有限公司 一种用液相色谱法分离测定鲁拉西酮及其光学异构体的方法
CN104140421B (zh) * 2013-05-08 2017-04-05 上海医药工业研究院 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用
WO2015143145A1 (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
EP3662919A1 (en) 2015-08-31 2020-06-10 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
WO2024091523A1 (en) * 2022-10-24 2024-05-02 2A Biosciences, Inc. Conformationally restricted phenethylamine analogs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366172A (en) * 1977-09-29 1982-12-28 The Upjohn Company 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use
JPH0625181B2 (ja) * 1985-03-27 1994-04-06 住友製薬株式会社 新規なイミド誘導体
US5219879A (en) * 1990-03-05 1993-06-15 Du Pont Merck Pharmaceutical Company Heterocyclic steroid compounds
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
IT1242929B (it) * 1990-11-07 1994-05-18 Nordica Spa Struttura di leva per calzature sportive, particolarmente per scarponi da sci
WO1996014297A1 (fr) * 1994-11-04 1996-05-17 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de lactame
JP3775823B2 (ja) * 1995-06-09 2006-05-17 大日本住友製薬株式会社 新規なイミド誘導体
CA2394548A1 (en) * 1999-12-17 2001-06-21 Joseph P. Yevich Antipsychotic heterocycle compounds
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
CN1826338B (zh) 2003-06-23 2011-07-13 大日本住友制药株式会社 老年性痴呆症治疗药
US7605260B2 (en) 2003-07-29 2009-10-20 Dainippon Sumitomo Pharma Co., Ltd. Process for producing imide compound
US20070160537A1 (en) 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
UA96015C2 (en) 2007-04-04 2011-09-26 Mepk Шарп Энд Доме Корп. Therapeutic agents
US20090076027A1 (en) 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched lurasidone
US20110003994A1 (en) 2009-07-02 2011-01-06 Dainippon Sumitomo Pharma Co., Ltd. Cycloalkane derivative

Also Published As

Publication number Publication date
US9867821B2 (en) 2018-01-16
HRP20130041T8 (en) 2013-03-31
GT200900258A (es) 2011-10-18
KR20090127416A (ko) 2009-12-11
ZA200906525B (en) 2010-04-28
JP2010523567A (ja) 2010-07-15
MY153868A (en) 2015-03-30
CN101675046B (zh) 2013-02-06
US20120316181A1 (en) 2012-12-13
HK1134291A1 (en) 2010-04-23
US8252799B2 (en) 2012-08-28
MA31323B1 (fr) 2010-04-01
CR11047A (es) 2009-10-23
ES2398312T3 (es) 2013-03-15
IL201235A (en) 2013-12-31
PL2144905T3 (pl) 2013-04-30
BRPI0809492A2 (pt) 2014-09-23
KR101562835B1 (ko) 2015-10-23
EP2144905A1 (en) 2010-01-20
EP2144905B1 (en) 2012-11-28
WO2008124030A1 (en) 2008-10-16
NI200900175A (es) 2010-09-07
SV2009003380A (es) 2010-04-13
IL201235A0 (en) 2010-05-31
RU2009136592A (ru) 2011-04-20
US20130178481A1 (en) 2013-07-11
JP5097265B2 (ja) 2012-12-12
HRP20130041T1 (hr) 2013-02-28
RS52661B (en) 2013-06-28
ECSP099674A (es) 2009-11-30
US20100105697A1 (en) 2010-04-29
CA2682494C (en) 2011-10-11
UA96015C2 (en) 2011-09-26
JP5686780B2 (ja) 2015-03-18
CO6300938A2 (es) 2011-07-21
SI2144905T1 (sl) 2013-03-29
JP2013028626A (ja) 2013-02-07
AU2008236705B2 (en) 2014-01-23
CA2682494A1 (en) 2008-10-16
DOP2009000232A (es) 2016-11-15
MX2009010678A (es) 2009-10-23
CN101675046A (zh) 2010-03-17
AU2008236705A1 (en) 2008-10-16
NZ580167A (en) 2012-02-24
CY1113649T1 (el) 2016-10-05
DK2144905T3 (da) 2013-03-11
US8410111B2 (en) 2013-04-02
RU2468025C2 (ru) 2012-11-27

Similar Documents

Publication Publication Date Title
EP2117311A4 (en) THERAPEUTICS
HRP20130041T8 (en) Therapeutic agents
GB0811304D0 (en) Therapeutic agents
GB0609492D0 (en) Therapeutic agents
GB0608928D0 (en) Therapeutic agents
GB0601962D0 (en) Therapeutic agents
GB0811643D0 (en) New therapeutic agents
GB0819593D0 (en) Therapeutic agents
GB0616214D0 (en) Therapeutic Agents
GB0723747D0 (en) Therapeutic agents
GB0821693D0 (en) Therapeutic agents
GB0611152D0 (en) Therapeutic agents
GB0812309D0 (en) Therapeutic agents
GB0805818D0 (en) Therapeutic agents
GB0724340D0 (en) Novel Therapeutic Agents
GB0801081D0 (en) Therapeutic agents
GB0801080D0 (en) Therapeutic agents
GB0620818D0 (en) Therapeutic agents
GB0620059D0 (en) Therapeutic agents
GB0609676D0 (en) Therapeutic agents
EP2140876A4 (en) THERAPEUTIC AGENT COMPRISING VASOHIBINE
GB0723748D0 (en) Therapeutic agents
EP2454276A4 (en) THERAPEUTIC AGENTS
GB0808690D0 (en) Therapeutic use
GB0622195D0 (en) Therapeutic agents